RR is a 35 year-old man who has come to see you prior to travel to Africa. He is going to help design a water treatment plant in a rural community. He has been healthy with the exception of a controlled seizure disorder and recent treatment for major depression, for which he is taking Zoloft. In review of the CDCâ€™s travel site you note that he is traveling to a region with chloroquine-resistant falciparum malaria. Which of the following should NOT be used for malaria prophylaxis for Mr. R? A) DEET based mosquito repellants B) Doxycycline daily prophylaxis C) Lariam (Mefloquine) weekly prophylaxis D) Malarone (Atovaquone + Progunail) daily prophylaxis E) Mosquito netting at night c The use of nocturnal barriers and repellants are recommended for all travelers to endemic malarial regions. All of the antimalarials listed are effective prophylactic agents for chloroquine-resistant malaria. Lariam (Mefloquine) is not recommended for persons with a history of major depression or seizures. In a patient without this history, Lariamâ€™s weekly dosing interval would be preferable to the daily regimens required for Malarone and Doxycycline.